Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. (NVAX) rose 3.51% to $7.97 on Monday, outperforming its competitors during a strong trading session for the broader market. This rise ended a two-day losing streak for the stock. The NASDAQ Composite Index and Dow Jones Industrial Average also saw gains, indicating a positive market trend.
Behavioral Patterns of NVAX and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Novavax Inc. (NVAX), identifying weak near and mid-term sentiment but a strong long-term outlook. It presents an exceptional 64.0:1 risk-reward setup targeting a 16.8% gain and outlines specific position, momentum, and risk-hedging trading strategies generated by AI models. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Novavax Inc stock: Biotech innovator or fading COVID play?
Novavax Inc is navigating the post-pandemic market with its recombinant protein platform, moving beyond its COVID-19 vaccine to focus on combination vaccines and broader infectious disease applications. While analysts are divided, with a consensus "Hold" rating, the company's long-term promise lies in its innovative vaccine technology and potential partnerships. Investors should monitor clinical trial readouts, earnings, and regulatory approvals given the high risks and volatility associated with biotech stocks.
Novavax (NASDAQ:NVAX) Shares Down 5.4% - Should You Sell?
Novavax (NVAX) shares dropped 5.4% to $7.585 on Thursday, with trading volume significantly below average, despite the company exceeding Q4 earnings expectations with an EPS of $0.11 against a consensus of -$0.66 and a 66.6% revenue increase year-over-year. Analysts have mixed ratings, leading to a "Hold" consensus with an average price target of $11.88, although some firms have raised targets to $16-$19. The company's market cap stands at $1.24 billion, and institutional investors hold 53.04% of its stock.
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. (NVAX) shares dropped by 3.99% on Thursday, concluding the trading session at $7.70. This underperformance occurred on a mixed day for the broader market, with the NASDAQ Composite rising and the Dow Jones Industrial Average falling slightly. This marks the second consecutive day of losses for Novavax stock.
Novavax Inc. stock underperforms Wednesday when compared to competitors
Novavax Inc. (NVAX) shares fell by 1.47% on Wednesday, closing at $8.02, despite a positive trading session for the broader stock market. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains. Novavax's stock is currently 33.00% below its 52-week high of $11.97.
Shah Capital Management Purchases 2,747,000 Shares of Novavax, Inc. $NVAX
Shah Capital Management significantly increased its stake in Novavax (NASDAQ:NVAX) during Q4, purchasing an additional 2,747,000 shares and bringing its total holdings to 14,558,780 shares, valued at $97.835 million. Novavax recently reported strong quarterly earnings, beating analyst expectations with $0.11 EPS and $136.4 million in revenue, a 66.6% year-over-year increase. Analyst sentiment for NVAX is mixed, with a "Hold" consensus rating and a target price of $11.88, although several analysts have "Buy" ratings with targets up to $19.00.
Novavax Inc. stock underperforms Monday when compared to competitors
Novavax Inc. (NVAX) shares fell 4.26% on Monday, closing at $8.09, marking its third consecutive day of losses. This occurred during a mixed trading session where the Dow Jones Industrial Average rose slightly, and the NASDAQ Composite Index declined. The article highlights Novavax's underperformance compared to its competitors.
Novavax names new R&D chief as previous leader departs after less than two years
Novavax has appointed an internal candidate as its new head of research and development. This promotion follows the departure of the previous R&D executive, who held the position for only 16 months. The article, by Sara Gilgore of the Washington Business Journal, notes this leadership change in the pharmaceutical company.
After 30 years in vaccines, Robert Walker takes over Novavax R&D
Novavax appointed Dr. Robert Walker as Executive Vice President and Head of Research & Development, effective March 30, 2026. Dr. Walker, a pulmonologist with extensive experience in drug and vaccine development, will oversee preclinical and clinical R&D, focusing on data generation for partnerships and Matrix adjuvant innovation. This internal promotion reflects confidence in his leadership as Novavax continues its strategic execution around partnerships and technology.
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Novavax (Nasdaq: NVAX) has announced the appointment of Dr. Robert Walker, MD, as its new Executive Vice President and Head of Research & Development. Dr. Walker, who previously served as Chief Medical Officer and has over 30 years of experience in drug and vaccine development, will now report directly to President and CEO John C. Jacobs. In his new role, he will be responsible for overseeing Novavax’s preclinical and clinical research and development functions, focusing on advancing scientific efforts and ensuring operational excellence.
Novavax names Robert Walker as R&D head
Novavax Inc. has appointed Dr. Robert Walker as Executive Vice President and Head of Research & Development. Dr. Walker previously served as the company’s Chief Medical Officer since 2022 and brings over 30 years of experience in drug and vaccine development. This appointment comes as Novavax reported strong financial results for Q4 2025, with EPS and revenue significantly surpassing expectations.
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Novavax, Inc. has announced the appointment of Dr. Robert Walker as Executive Vice President and Head of Research & Development. Dr. Walker, who previously served as Novavax's Chief Medical Officer, will focus on advancing the company's R&D efforts, including data generation for partnerships, Matrix adjuvant innovation, and pipeline development. He brings over 30 years of experience in drug and vaccine development to his new role.
Novavax, Inc. Trade Ideas — BSESOF:NVV1
This article compiles various trade ideas and analyses for Novavax (NVV1/NVAX) from different traders on TradingView. The ideas range from strong bullish predictions based on vaccine efficacy and revenue projections to warnings of potential corrections due to overbought conditions. Several posts highlight the company's COVID-19 vaccine trial results and supply agreements as key drivers for stock performance.
Novavax, Inc. Trade Ideas — BSESOF:NVV1
This article compiles various trade ideas and analyses for Novavax, Inc. (NVV1) from different traders on TradingView. The ideas cover a range of sentiments from bullish to bearish, discussing technical indicators, market trends, efficacy of their COVID-19 vaccine, and news surrounding FDA and European approvals. Traders share potential entry/exit points, stop losses, and price targets based on their individual strategies and market observations.
Novavax, Inc. Trade Ideas — BSESOF:NVV1
This page compiles various trading ideas and analyses for Novavax, Inc. (NVV1/NVAX) from different traders on TradingView. The analyses cover technical setups, potential breakouts, fundamental catalysts like the Pfizer licensing agreement, and target prices ranging from short-term gains to significantly higher long-term valuations. Many traders express a bullish outlook, citing bottoming patterns, volume shifts, and the company's vaccine technology, though some also highlight the stock's volatility and the importance of risk management.
ETFs Investing in Novavax, Inc. Stocks
This article lists various ETFs that hold Novavax, Inc. stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs listed cross different categories like biotechnology, small-cap, and healthcare, offering investors diverse opportunities and lower risk exposure to Novavax.
Equity in earnings of Novavax, Inc. – BSESOF:NVV1
This article provides a financial overview of Novavax, Inc. (BSESOF:NVV1), focusing on its equity in earnings. It presents a table showing period values, changes, and percentage changes related to the company's earnings. The content is concise, primarily highlighting financial data for the specified period.
Novavax (NVAX) Stock Trades Down, Here Is Why
Shares of Novavax (NVAX) fell 4.1% following a broad market downturn attributed to escalating uncertainty from the U.S.-Iran conflict and rising oil prices, alongside investor concerns about delayed interest rate cuts. The company's stock is highly volatile, experiencing frequent large moves, but today's decline suggests the market views the geopolitical news as impactful but not fundamentally altering the business perception. Despite a 20% gain year-to-date, NVAX is still trading significantly below its 52-week high, and long-term investors have seen substantial value erosion.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc. (NVAX) shares dropped 5.59% to $8.45 on Friday, underperforming competitors during a broad market decline where the NASDAQ Composite and Dow Jones Industrial Average also fell. This marked the stock's second consecutive day of losses.
Novavax Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates
Novavax Inc. (NVAX) faces renewed investor scrutiny due to post-COVID revenue declines and ongoing pipeline developments, particularly new combination vaccine candidates. While pipeline progress offers optimism for government contracts and market share recapture, the company grapples with financial concerns, including dwindling cash reserves and the need for diversification beyond its COVID vaccine. Regulatory decisions and partnership deals are critical catalysts for the stock, as Novavax aims to establish a multi-product respiratory franchise amidst intense competition and sector volatility.
Novavax Inc. stock underperforms Thursday when compared to competitors
Shares of Novavax Inc. (NVAX) experienced a 4.18% decline on Thursday, closing at $8.95. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and Dow Jones Industrial Average also falling. The stock's closing price was 25.23% below its 52-week high, which was achieved in February.
Novavax Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates
Novavax Inc. (NVAX) navigates post-COVID revenue declines and advances new vaccine candidates, including combination shots for COVID-19 and influenza, attracting investor attention for potential turnaround. Despite past volatility and financial challenges, the company's reliance on pipeline progress, FDA decisions, and strategic partnerships are key catalysts for future growth in a competitive biotech landscape. US investors are closely monitoring Novavax's regulatory milestones and financial health as it shifts towards a diversified respiratory vaccine portfolio.
Novavax Inc. stock underperforms Tuesday when compared to competitors
Novavax Inc. (NVAX) shares fell 4.73% on Tuesday to $9.26, underperforming the broader market indexes like the NASDAQ Composite and Dow Jones Industrial Average. The stock closed 22.64% below its 52-week high.
(NVAX) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Novavax Inc. (NVAX), highlighting a mid-channel oscillation pattern and a strong risk-reward setup targeting an 17.8% gain with minimal risk. It discusses divergent sentiment across different time horizons and outlines three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating varying signal strengths and support/resistance levels.
Novavax Inc. stock rises Monday, still underperforms market
Novavax Inc. (NVAX) stock increased by 1.04% to $9.72 on Monday, breaking a three-day losing streak. Despite this gain, the stock underperformed the broader market, as both the NASDAQ Composite Index and the Dow Jones Industrial Average saw larger increases of 1.38%.
Q3 Earnings Estimate for Novavax Issued By Zacks Research
Zacks Research has issued its Q3 2027 earnings per share estimate for Novavax (NASDAQ:NVAX) at a loss of ($0.01) per share, with a full-year consensus estimate of ($1.46) per share. The biopharmaceutical company recently beat Q4 expectations, reporting $0.11 EPS against a ($0.66) consensus and revenue up 66.6% year-over-year. Novavax's stock currently trades around $9.62, with analysts holding an average "Hold" rating and a consensus price target of $11.88.
NVAX SEC Filings - Novavax Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Novavax (NVAX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details recent significant events such as milestone payments from Sanofi, FDA approvals for COVID-19 vaccines, and convertible note transactions that impact the company's financial structure. The platform also offers AI-powered summaries of these documents to help investors understand their implications.
NVAX SEC Filings - Novavax Inc 10-K, 10-Q, 8-K Forms
This page provides access to Novavax Inc.'s SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed regulatory disclosures. It highlights key events like executive stock transactions, collaboration agreements with companies like Pfizer and Sanofi, and financial reports with AI-powered summaries for easier understanding. The filings cover various material events, financial performance, and insider activities, updated in near real-time.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc.'s stock (NVAX) fell 1.23% to $9.62 on Friday, experiencing its third consecutive day of losses. This underperformance occurred during a generally negative trading session, with the NASDAQ Composite Index and Dow Jones Industrial Average also declining.
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. (NVAX) shares dropped 2.70% to $9.74 on Thursday, contributing to its second consecutive day of losses. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing declines.
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages
Novavax, Inc. (NASDAQ:NVAX) has received a consensus "Hold" rating from ten brokerages, with an average 12-month price target of $11.88. The company recently reported better-than-expected earnings of $0.11 EPS against an anticipated -$0.66, and revenue of $136.4 million, marking a 66.6% year-over-year increase. Despite institutional investors increasing their stakes, the stock's market capitalization stands at $1.63 billion with a high debt-to-equity ratio of 5.93.
Novavax Inc. stock underperforms Wednesday when compared to competitors
Novavax Inc. (NVAX) shares fell 5.92% to $10.01 on Wednesday, underperforming the broader market as the NASDAQ Composite Index dropped 1.46% and the Dow Jones Industrial Average declined 1.63%. The stock closed 16.37% below its 52-week high of $11.97, achieved on February 26th. The article highlights the company's stock performance relative to the overall market on a specific trading day.
Novavax (NASDAQ:NVAX) Trading 7.6% Higher - Should You Buy?
Novavax (NVAX) shares rose 7.6% to $10.85 during mid-day trading on Tuesday. Analyst sentiment is mixed, with an average "Hold" rating and an average price target of $11.88, reflecting a range of opinions from a $6 underweight to a $19 buy target. Although Novavax beat quarterly earnings and revenue estimates, it faces high leverage and analysts still project a negative full-year EPS.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares surged by 5.56% to $10.64 on Tuesday, outperforming the broader market which also saw gains in the NASDAQ Composite Index and the Dow Jones Industrial Average. This increase ended a three-day losing streak for the company's stock. The positive performance occurred during a strong trading session for the stock market overall.
Here’s What You Should Understand Besides the Reason Novavax, Inc. (NVAX) is Gaining Attention
Novavax (NVAX) has recently garnered significant investor interest, outperforming the S&P 500 and its sector over the past month. The article emphasizes the importance of earnings estimate changes as key drivers of long-term stock performance, detailing Novavax's projected losses for the current quarter and fiscal year but highlighting recent positive earnings surprises. It concludes that while Novavax holds a Zacks Rank #3 (Hold), indicating it may perform in line with the broader market, investors should consider various factors to make informed decisions.
Novavax Inc. stock underperforms Monday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.51% to $10.08 on Monday, marking its third consecutive day of losses. This underperformance occurred despite a strong trading session for the broader market, with both the NASDAQ Composite Index and the Dow Jones Industrial Average posting significant gains.
Farallon Capital Management LLC Purchases 764,000 Shares of Novavax, Inc. $NVAX
Farallon Capital Management LLC significantly increased its stake in Novavax, Inc. (NVAX) by purchasing an additional 764,000 shares, bringing its total ownership to 780,000 shares. This move by Farallon is part of a broader trend of institutional investment in Novavax, with other hedge funds also adjusting their holdings. Analysts have a mixed outlook on Novavax, with several "buy" and "hold" ratings, and an average target price of $11.88.
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform
Jefferies has reiterated a Buy rating and a $25.00 price target on Novavax Inc. (NASDAQ:NVAX), citing the company's capital-light adjuvant platform as a key growth driver beyond its COVID-19 vaccine business. This positive outlook follows Novavax's strong fourth-quarter 2025 earnings report, which significantly surpassed expectations for both EPS and revenue. The firm emphasizes the broad applicability of Novavax's Matrix-M adjuvant across various medical fields and highlights strategic partnerships, like the one with Sanofi, for efficient growth.
How (NVAX) Movements Inform Risk Allocation Models
This article analyzes Novavax Inc. (NVAX) using AI models, highlighting strong sentiment across all time horizons. It provides specific institutional trading strategies for long, breakout, and short positions, including entry zones, targets, and stop losses. The analysis also details multi-timeframe signal strengths, support, and resistance levels for risk allocation models.
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026
Jefferies has maintained its Buy rating on Novavax, Inc. (NVAX) as of March 12, 2026, citing the company's "capital-light adjuvant platform with improving line-of-sight." The firm emphasized the platform's economics and clearer development pathways as key reasons for its positive stance, without issuing a new price target in this specific note. Meyka AI also rates NVAX with a B+ grade, factoring in various market and financial metrics.
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. (NVAX) shares dropped 4.63% to $10.30 on Thursday, underperforming the broader stock market which saw declines in both the NASDAQ Composite Index and the Dow Jones Industrial Average. This fall ended a three-day winning streak for Novavax's stock.
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability
Novavax (NVAX) reported strong fourth-quarter and full-year 2025 results, achieving US$1.12 billion in revenue and US$440.3 million in net income for the year, marking a return to profitability. Despite a recent surge in stock price (24.14% in 30 days, 51.47% year-to-date), the stock is considered 21.6% undervalued with a fair value estimate of $13.78 against a current price of $10.80. However, analysts note potential pressure points including expected shrinking revenues, changing margins, and reliance on partner execution and COVID vaccine demand.
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028
Novavax (NVAX) is pursuing a strategy focused on platform partnerships and innovation, aiming for profitability by 2028. The company has secured significant deals with Sanofi and Pfizer, leveraging its Matrix-M technology, and is advancing its R&D pipeline in vaccines and immunotherapies. This approach is supported by financial discipline and a strong intellectual property position.
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms
Novavax Inc.'s EVP and Chief Legal Officer, Mark J. Casey, filed an amended Form 4 (4/A) to update the exercise price for a previously reported non-statutory stock option covering 152,000 shares. The option was granted on March 2, 2026, with an exercise price of $10.11 and vests over four years, contingent on continued employment. All other details from the original filing remain unchanged.
Novavax (NVAX) EVP granted 177,500 options with revised terms
Novavax's EVP and Chief Strategy Officer, Elaine O’Hara, filed an amended Form 4 to correct the exercise price for a previously reported 2026 non-statutory stock option grant of 177,500 shares. The original grant was made on March 2, 2026, and the amendment clarifies the exercise price while all other terms, including the vesting schedule, remain unchanged. One-quarter of the shares vest on the first anniversary, with the rest vesting monthly over the subsequent three years, contingent on continued employment.
Novavax (NVAX) EVP granted 139,500 non-statutory stock options
Novavax's Executive Vice President of Research and Development, Ruxandra Draghia-Akli, received a grant of 139,500 non-statutory stock options. An amended SEC Form 4/A was filed solely to correct the exercise price of these options, with all other details including the grant date of March 2, 2026, and the vesting schedule remaining unchanged. The options vest over four years, with a quarter vesting on the first anniversary and the remainder in equal monthly installments over the subsequent three years, contingent on continued employment.
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue
Novavax (NVAX) recently reported a significant turnaround in its financial performance, moving from full-year losses to profits in 2025 due to increased vaccine revenues and cost control. This shift is reinforcing an investment narrative that focuses on the value of its protein-based vaccines and Matrix-M adjuvant, especially given a new licensing agreement with Pfizer. Investors are now considering how the company's reliance on partner-driven milestones and royalties will balance against potential future pressures on vaccine revenue.
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability
Novavax (NVAX) achieved a significant turnaround in Q4 2025, reporting a return to profitability with net income of US$17.53 million on revenue of US$147.14 million. The company's full-year revenue reached US$1.12 billion with a net income of US$440.3 million. Despite recent share price momentum, the stock is considered undervalued at US$9.89 compared to a narrative fair value of US$13.78, driven by licensing agreements with Sanofi and Pfizer.
[Form 4] NOVAVAX INC Insider Trading Activity
This article details the recent insider trading activities of Novavax Inc.'s EVP and Chief Legal Officer, Mark J. Casey, as reported in a Form 4 SEC filing. The filing indicates he received restricted stock units and stock options on March 2, 2026, and exercised some restricted stock units on March 1, 2026, with shares withheld for tax purposes. These transactions show ongoing equity-based compensation and adjustments to his holdings in Novavax.
